Abstract

We attempt to discuss the improvement of clinical efficacy of erythromycin combined with oseltamivir phosphate granules in children with mycoplasma pneumonia and its influence on lung function and infection indicators. We selected 60 patients with mycoplasma pneumonia in children from February 2019 to June 2020 and randomly divided them into observation group (30 cases of erythromycin combined with oseltamivir phosphate granules) and control group (oseltamivir phosphate) Wei granule treatment (30 cases), compare the clinical effective rate, changes in various indicators of lung function, disappearance time of clinical symptoms and changes in serum procalcitonin, C-reactive protein and interleukin 6 concentration levels in both groups before and after treatment. Observation group possessed remarkably higher ratio of time to peak tidal expiratory flow to total expiratory time, ratio of instantaneous velocity to tidal peak expiratory velocity at 75 % tidal volume and tidal volume than control group (p<0.05); and it had remarkably lower antipyretic time, rales disappearance time, throat and tonsil hyperemia disappearance time than control group (p<0.05); observation group possessed remarkably lower length of stay than control group (p<0.05) and procalcitonin, interleukin 6 and C-reactive protein concentration in serum of observation group declined more than control group (p<0.05). The total clinical effective rate of observation group (93.4 %) was remarkably higher than control group (80 %) (p<0.05). Erythromycin combined with oseltamivir phosphate particles can remarkably improve the clinical effectiveness of mycoplasma pneumonia in children, improve lung signs and clinical effectiveness and reduce procalcitonin, C-reactive protein and interleukin 6 concentration in serum. Effective treatment of pneumonia provides clinical guidance value.